Fri, Sep 19, 2014, 2:23 PM EDT - U.S. Markets close in 1 hr 37 mins

Recent

% | $
Quotes you view appear here for quick access.

Rosetta Genomics, Ltd. Message Board

  • mrbub23@sbcglobal.net mrbub23 Mar 15, 2013 2:32 PM Flag

    SOMEBODY IS DEFINITELY ! ACCUMULATING AT $4.50 RANGE VERY QUIETLY......

    WEEKS OF ACCUMULATION, DRAWING LITTLE ATTENTION. DISCIPLINED SHORT COVERING AND STEADY ACQUIRING SHARES!

    LOOK AT ROSG WEBSITE
    2013 CORPORATE OVERVIEW

    ACHIEVEMENTS AND $$$UPCOMING MILESTONES $$$

    SEE WHAT IS HIGHLIGHTED IN BLACK
    "GAIN TRACTION WITH US SALES miRview mets2" !!!!!!!!

    also....

    "ONGOING DISCUSSIONS FOR POTENTIAL BUSINESS DEVELOPMENT OPPORTUNITIES"

    WE MAY BE ON THE VERGE OF SOME VERY POSITIVE NEWS PERTAINING TO RO$G :)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ACCUMULATION? WHY IS VOLUME DECREASING?

      Mar 11, 2013 4.54 4.79 4.50 4.51 178,100 4.51
      Mar 4, 2013 4.41 4.94 4.34 4.50 219,800 4.50
      Feb 25, 2013 4.61 4.69 4.40 4.45 135,300 4.45
      Feb 19, 2013 4.71 4.78 4.36 4.58 263,300 4.58
      Feb 11, 2013 5.18 5.48 4.65 4.69 687,100 4.69
      Feb 4, 2013 4.55 5.17 4.48 5.14 499,700 5.14
      Jan 28, 2013 4.69 4.95 4.42 4.56 356,600 4.56
      Jan 22, 2013 4.60 4.82 4.40 4.64 359,300 4.64
      Jan 14, 2013 4.98 4.99 4.55 4.62 252,200 4.62
      Jan 7, 2013 4.71 5.98 4.53 4.98 1,777,000

    • I agree. The Meso thing looks like another promising line that will add some sales. The partnership with the The Mesothelioma Center will drive sales. This test is the only one currently on the market that will give definite diagnosis of mesothelioma vs other types of lung cancer.

 
ROSG
3.61-0.21(-5.50%)1:44 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.